Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Takayuki KatsubeRyosuke ShimizuTakahiro FukuharaTakeshi KanoToshihiro WajimaPublished in: Clinical pharmacokinetics (2020)
The modelling and simulation support lusutrombopag 3 mg once daily for 7 days without platelet monitoring.
Keyphrases